CALC

CalciMedica, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001534133

$0.9580 -9.62% $14.4M

Vol

Market Cap$14.4M

Cap SizeNano Cap

Inst. Holders4 funds

Inst. Value$3.3M

Inst. Activity1 buys / 0 sells

Reddit Sentiment63° Warm

SEC Reports3

Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001534133·Prev Close $1.06

Recent Activity

May 12, 2026 SEC

CalciMedica reported Q1 2026 GAAP net income of $5.0M ($0.31 basic EPS), a swing from a $5.0M net loss in Q1 2025, drive

8-K — Impact 4/10

Mar 12, 2026 SEC

CalciMedica, Inc. (CALC) has had an S-3 shelf registration statement declared effective by the SEC, allowing the company

EFFECT — Impact 4/10

Mar 3, 2026 SEC

CalciMedica filed an S-3 shelf registration, signaling potential future share issuance. The company has a market cap of

S-3 — Impact 6/10

Apr 5, 2025 Insider

Hebbar Sudarshan sold 91,173 shares

Chief Medical Officer @ $0.00 ($0.00)

Apr 5, 2025 Insider

Roberts Eric W sold 83,358 shares

CHIEF BUSINESS OFFICER @ $0.00 ($0.00)

Apr 5, 2025 Insider

Dunn Michael J. sold 65,124 shares

President and COO @ $0.00 ($0.00)

Inst.

RENAISSANCE TECHNOLOGIES LLC — ADD

88,300 shares ($581.9K)

Inst.

RENAISSANCE TECHNOLOGIES LLC — ADD

70,000 shares ($215.3K)

Price Targets

Historical data — last covering-analyst action Mar 2026. No current recommendation available.

$10.33 (Mar 2026)

Current $0.9100 Low $6.00 Median $10.00 High $15.00 3 analysts

$6.00 $15.00

Analyst Ratings

Historical distribution80% buy · 10 analysts · last covering-analyst action Mar 2026

3Strong Buy

5Buy

2Hold

0Sell

0Strong Sell

Historical Analyst Actions

Date	Firm	Action	Rating
Mar 5, 2026	Oppenheimer	MAINTAIN	Outperform → Outperform
Jan 29, 2026	HC Wainwright & Co.	DOWNGRADE	Buy → Neutral

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-0.26 ▲ +9.2%	$-0.33 — $-0.22	34% YoY	3
Next Q	$-0.33 ▼ -9.3%	$-0.42 — $-0.22	36% YoY	3
Current FY	$-0.62 ▲ +50.0%	$-0.83 — $-0.37	69% YoY	3
Next FY	$-1.96 ▲ +9.3%	$-3.58 — $-0.86	-217% YoY	3

Latest Reports

NEUTRAL 8-K 4/10

CalciMedica reported Q1 2026 GAAP net income of $5.0M ($0.31 basic EPS), a swing from a $5.0M net loss in Q1 2025, drive

May 12, 2026

NEUTRAL EFFECT 4/10

CalciMedica, Inc. (CALC) has had an S-3 shelf registration statement declared effective by the SEC, allowing the company

Mar 12, 2026

Top Institutional Holders

Fund	Value	Move
VANGUARD GROUP INC	$2.7M	—
RENAISSANCE TECHNOLOGIES LLC	$581.9K	ADD
BANK OF AMERICA CORP	$59.5K	—
WELLS FARGO & COMPANY/MN	$66.00	—

Recent Insider Trades

Date	Insider	Type	Value
Apr 5, 2025	Hebbar Sudarshan	A	$0.00
Apr 5, 2025	Roberts Eric	A	$0.00
Apr 5, 2025	Dunn Michael	A	$0.00
Apr 5, 2025	Stauderman Kenneth	A	$0.00
Apr 5, 2025	Leheny A.	A	$0.00

Reddit Sentiment

63°

Warm

Bearish Neutral Bullish

4 mentions 2 bullish 0 bearish

4 institutional holders with $3.3M total value (505,138 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, BANK. Net buying activity: 1 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#	Fund	Shares	Value	% of Tracked	Last Move
1	VANGUARD GROUP INC	407,801	$2.7M	80.7%	—
2	RENAISSANCE TECHNOLOGIES LLC	88,300	$581.9K	17.5%	ADD +26.1%
3	BANK OF AMERICA CORP /DE/	9,027	$59.5K	1.8%	—
4	WELLS FARGO & COMPANY/MN	10	$66.00	0.0%	—

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
RENAISSANCE TECHNOLOGIES LLC	ADD	70,000	88,300	+26.1%	$581.9K	2025-Q4
RENAISSANCE TECHNOLOGIES LLC	ADD	36,000	70,000	+94.4%	$215.3K	2025-Q3
UBS Group AG	NEAR_EXIT	17,003	17	-99.9%	$52.00	2025-Q3
UBS Group AG	DOUBLED	220	17,003	+7628.6%	$27.2K	2025-Q2
UBS Group AG	TRIM	325	220	-32.3%	$421.00	2025-Q1
RENAISSANCE TECHNOLOGIES LLC	NEW	—	43,200	—	$152.9K	2024-Q4
UBS Group AG	DOUBLED	15	325	+2066.7%	$1.1K	2024-Q4

6 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
Apr 5, 2025	Hebbar Sudarshan	Chief Medical Officer	A	91,173	$0.00	$0.00
Apr 5, 2025	Roberts Eric W	CHIEF BUSINESS OFFICER	A	83,358	$0.00	$0.00
Apr 5, 2025	Dunn Michael J.	President and COO	A	65,124	$0.00	$0.00
Apr 5, 2025	Stauderman Kenneth A.	Chief Scientific Officer	A	65,124	$0.00	$0.00
Apr 5, 2025	Leheny A. Rachel	CHIEF EXECUTIVE OFFICER	A	148,482	$0.00	$0.00
Apr 5, 2025	Bardin Stephen	Chief Financial Officer	A	67,728	$0.00	$0.00

3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.7/10.

NEUTRAL 8-K 4/10

CalciMedica reported Q1 2026 GAAP net income of $5.0M ($0.31 basic EPS), a swing from a $5.0M net lo

May 12, 2026

NEUTRAL EFFECT 4/10

CalciMedica, Inc. (CALC) has had an S-3 shelf registration statement declared effective by the SEC,

Mar 12, 2026

BEARISH S-3 6/10

CalciMedica filed an S-3 shelf registration, signaling potential future share issuance. The company

Mar 3, 2026

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Historical analyst distribution (last covering-analyst action Mar 2026): 80% buy across 10 analysts — 3 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.

Analyst Price Targets

Historical data — last covering-analyst action Mar 2026. No current recommendation available.

$10.33 mean target (Mar 2026)

$6.00 Low $15.00 High

Metric	Value
Current Price	$0.9100
Target Low	$6.00
Target Mean	$10.33
Target Median	$10.00
Target High	$15.00
# Analysts	3
Recommendation	— (no recent coverage)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-0.26	$-0.33	$-0.22	34.2%	+9.2%	1↑ 0↓	$0.0B	0.0%	3
Next Q 2026-09-30	$-0.33	$-0.42	$-0.22	35.9%	-9.3%	2↑ 0↓	$0.0B	0.0%	3
Current FY 2026-12-31	$-0.62	$-0.83	$-0.37	68.7%	+50.0%	1↑ 0↓	$0.0B	0.0%	3
Next FY 2027-12-31	$-1.96	$-3.58	$-0.86	-217.3%	+9.3%	1↑ 2↓	$0.0B	0.0%	3

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.263
7d ago	$-0.290	+0.027
30d ago	$-0.290	+0.027
60d ago	$-0.290	+0.027
90d ago	$-0.540	+0.277

2 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.

Historical Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Mar 5, 2026	Oppenheimer	MAINTAIN	Outperform	Outperform
Jan 29, 2026	HC Wainwright & Co.	DOWNGRADE	Buy	Neutral

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Jun 1, 2026	3	5	2	80%
May 1, 2026	3	5	2	80%
Apr 1, 2026	3	5	2	80%
Mar 1, 2026	3	5	2	80%
Feb 1, 2026	3	5	2	80%
Jan 1, 2026	3	6	1	90%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

63°

Warm

Bearish Neutral Bullish

4 mentions 2 bullish 0 bearish 4 time periods

Reddit Sentiment History

Date	Mentions	Sentiment	Bullish	Threads
Apr 7, 2026	1	50° Neutral	0	1
Apr 7, 2026	1	50° Neutral	0	1
Apr 7, 2026	1	60° Warm	1	1
Apr 7, 2026	1	60° Warm	1	1

Recent Reddit Threads

r/pennystocks Neutral 2mo ago

CALC Deleted his post 5h after posting it

▲ 1 💬 0 ⚡ 0.5

r/pennystocks Bullish 2mo ago

CalciMedica ($CALC): A Dual Mechanism Drug With Peer Reviewed Phase 2b Data in a Zero Competitor Indication at $9M Market Cap. Make It Make Sense.

▲ 1 💬 1 ⚡ 0.5

May 18, 2026

earnings_calendar

CALC Q1 2026 Earnings Scheduled — 2026-05-18

Apr 1, 2026

Clinical Trial

A Study of Auxora in Patients With Critical COVID-19 Pneumonia

Phase Phase 2 — TERMINATED

Apr 1, 2026

Clinical Trial

A Study of Auxora in Patients With Severe COVID-19 Pneumonia

Phase Phase 2 — COMPLETED

Apr 1, 2026

Clinical Trial

CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS

Phase Phase 2 — COMPLETED